MedTrace Logo

Growth Factors Release of PRF and PRGF

NCT02447510 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-05-19

No results posted yet for this study

Summary

Background: platelet concentrate could enhance growth factors (GF) crevicular fluid levels which might be crucial to proper tissue repair and wound healing. However, the open usually contaminated nature of periodontal defects could affect negatively GF availability and activity. To test this assumption, this study was designed to evaluate levels of VEGF and PDGF-BB in gingival crevicular fluid (GCF) during the early stages of healing of localized intrabony defects treated with platelet rich in growth factor (PRGF) and platelet rich fibrin (PRF) as compared with xenograft defect filling control.

Methods: Thirty non-smoking patients with severe chronic periodontitis participated in this prospective, randomized and single blinded trial. Each patient contributed one interproximal defect that was randomly assigned to the bone substitute grafting control (n=10) G1, experimental PRGF (n=10) G2 and PRF (n=10) G3. Plaque index, gingival index, probing depth (PD), clinical attachment level (CAL) and the intrabony depth of the defect (IBD) were measured at baseline for patient enrollment. Gingival crevicular fluid (GCF) samples were collected on days 1 and 3, 7, 14, 21, and 30 days after therapy. The primary outcome variable was the change in VEGF and PDGF-BB levels for sites treated by PRGF and PRF compared to that of the xenograft treated cases.

Conditions

  • Periodontitis

Interventions

PROCEDURE

group 1 bio-oss bone xenograft

bone substitute (bio-oss)

PROCEDURE

group 2 platelet rich in growth factor (autogenous platelet rich in growth factor)

platelet rich in growth factor (autogenous platelet rich in growth factor)

PROCEDURE

group 3 platelet rich fibrin (autogenous platelet rich fibrin)

platelet rich fibrin (autogenous platelet rich fibrin)

Sponsors & Collaborators

  • Al-Azhar University

    lead OTHER

Principal Investigators

  • Ahmed Y Gamal, PhD · Ain Shams Universty

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02447510 on ClinicalTrials.gov